Leukotriene modifiers as novel therapeutics in asthma

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 5, 1998, Pages 147-153

  Leff, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HUMAN; ICOSANOID METABOLISM; INHALATIONAL DRUG ADMINISTRATION; LUNG LAVAGE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST;

EID: 0031735452     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.028s5147.x     Document Type: Conference Paper

References (43)

1. Feldberg W, Kellaway CH. Liberation of histamine and formation of lyscithin-like substances by cobra venom. J Physiol 1938; 94:187-226.
2. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995; 8:1203-13.
3. 4. Proc Natl Acad Sci USA 1983; 80:1712-6.
4. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126:449-51.
5. 4,: comparison of potency in canine trachea in vivo. Prostaglandins 1983; 25:237-43.
6. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989-90.
7. 4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997; 155:1247-53.
8. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89:1111-9.
9. Sampson AP, Castling DP, Green CP, Price JF. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995; 73:221-5.
10. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52:1030-5.
11. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447-51.
12. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-4.
13. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153:931-5.
14. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147:839-44.
15. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95:42-51.
16. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Int Med 1993; 119:1059-66.
17. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98:859-71.
18. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. Jama 1996; 275:931-6.
19. 4 in normal and in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1789-92.
20. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990; 141:988-92.
21. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Therapeutics 1997; 61:83-92.
22. Taylor IK, O'Shaughnessy KM, Fuller RM, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:691-4.
23. Hamilton AL, Faiferman I, Stober P, Watson PM, O'Byrne PM. Pranlukast (SB205312, ONO 1078), a leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. Eur Respir J 1997; 10:419S.
24. Diamant Z, Timmers MC, van den Veen H, et al. Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects. Am J Respir Crit Care Med 1996; 153:A346.
25. 4-receptor antagonist. N Engl J Med 1990; 323:1736-9.
26. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992; 145:746-9.
27. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Therapeutics 1997; 62:556-61.
28. Leff JA, Busse WW, Pearlman DS, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl J Med 1998; 339:147-52.
29. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153:65-9.
30. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Resp Med 1994; 88:363-8.
31. Dahlén B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6:1018-26.
32. 1 receptor antagonist: Correlations with patient's baseline characteristics. Eur Respir J 1997; 10:419S.
33. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-23.
34. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. Clin Therapeutics 1997; 19:675-90.
35. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52:523-7.
36. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Monteleukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch Intern Med 1998; 158:1213-20.
37. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Eur Respir J 1997; 10:437S.
38. Knorr BA, Matz J, Bernstein J, Nguyen H, Seidenberg BC, Reiss TF, Becker A. Montelukast for chronic asthma in 6-to 14-year old children. JAMA 1998; 279:1181-6.
39. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year old children with asthma. J Pediatrics 1998; 133:424-8.
40. Leff JA, Israel E, Noonan MJ, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. Am J Respir Crit Care Med 1997; 155:A976.
41. Calhoun WJ, Williams KL, Simonson SG, Lavins BJ. Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild asthma. Am J Respir Crit Care Med 1997; 155:A662.
42. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1997; 152:897-905.
43. Leff JA, Pizzichini E, Efthimiadis A, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 1997; 155:A977.